- Wealth PMS (50L+)
The big boy of the pharma sector, Dr. Reddys Laboratories has come out with its Q1 results for 2016. The results have not been taken well by investors and the stock is down by 14.61% in two consecutive trading sessions.
Dr. Reddy’s revenue is down by 14.52% compared to Q1 2015. However the net profits nose dived by 76.29% (compared to Q1FY16).
The company has received an FDA warning letter on 5th Nov 2015 for its plant Andhra Pradesh and Telangana. Dr Reddy’s had said it has filed a response to the FDA on 7th Dec 2015 and has been updating the progress of remedies undertaken periodically and is hoping the issue will be resolved.
Read our detailed Posts on Dr Reddys and its FDA hurdles:
You Might Also Like:
Nothing in this newsletter is financial advice and should not be construed as such. Please do not take trading decisions based solely on the matter above; if you do, it is entirely at your own risk without any liability to Capital Mind. This is educational or informational matter only, and is provided as an opinion.
Disclosure: The authors at Capital Mind have positions in the market and some of them may support or contradict the material given above, or may involve a direction derived from independent analysis.